Literature DB >> 15150119

Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells.

Ji-Hui Hao1, Ming Yu, Feng-Ting Liu, Adrian C Newland, Li Jia.   

Abstract

Previous studies have shown that the lymphoblastic leukemia CEM cell line is resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis because of a low expression of caspase-8. Bcl-2 inhibitors, BH3I-2' and HA14-1, are small cell-permeable nonpeptide compounds, are able to induce apoptosis by mediating cytochrome c release, and also lead to dissipation of the mitochondrial membrane potential (DeltaPsim). This study aimed to use the Bcl-2 inhibitors to sensitize CEM cells to TRAIL-induced apoptosis by switching on the mitochondrial apoptotic pathway. We found that a low dose of BH3I-2' or HA14-1, which did not induce cytochrome c release, greatly sensitized CEM cells to TRAIL-induced apoptosis. In a similar manner to the classical uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP), both BH3I-2' and HA14-1 induced a reduction in DeltaPsim, a generation of reactive oxygen species (ROS), an increased mitochondrial respiration, and a decreased ATP synthesis. This uncoupling function of the Bcl-2 inhibitors was responsible for the synergy with TRAIL-induced apoptosis. CCCP per se did not induce apoptosis but again sensitized CEM cells to TRAIL-induced apoptosis by uncoupling mitochondrial respiration. The uncoupling effect facilitated TRAIL-induced Bax conformational change and cytochrome c release from mitochondria. Inhibition of caspases failed to block TRAIL-mediated cell death when mitochondrial respiration was uncoupled. We observed that BH3I-2', HA14-1, or CCCP can overcome resistance to TRAIL-induced apoptosis in TRAIL-resistant cell lines, such as CEM, HL-60, and U937. Our results suggest that the uncoupling of mitochondrial respiration can sensitize leukemic cells to TRAIL-induced apoptosis. However, caspase activation per se does not represent an irreversible point of commitment to TRAIL-induced cell death when mitochondrial respiration is uncoupled.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15150119     DOI: 10.1158/0008-5472.CAN-03-3648

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Susceptibility of myelomonocytic leukemia U937 cells to the induction of apoptosis by the non-peptidic Bcl-2 ligand HA14-1 is cell cycle phase-dependent.

Authors:  John J Reiners; David Kessel
Journal:  Cancer Lett       Date:  2005-04-28       Impact factor: 8.679

Review 2.  BH3 mimetics to improve cancer therapy; mechanisms and examples.

Authors:  Lin Zhang; Lihua Ming; Jian Yu
Journal:  Drug Resist Updat       Date:  2007-10-24       Impact factor: 18.500

Review 3.  Combined modality therapy with TRAIL or agonistic death receptor antibodies.

Authors:  Hope M Amm; Patsy G Oliver; Choo Hyung Lee; Yufeng Li; Donald J Buchsbaum
Journal:  Cancer Biol Ther       Date:  2011-03-01       Impact factor: 4.742

4.  Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cells.

Authors:  Alexandra C Vrazo; Adrianne E Hontz; Sarah K Figueira; Braeden L Butler; Julie M Ferrell; Brock F Binkowski; Jinzhu Li; Kimberly A Risma
Journal:  Blood       Date:  2015-06-29       Impact factor: 22.113

Review 5.  Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease.

Authors:  Gunter P Eckert; Kathrin Renner; Schamim H Eckert; Janett Eckmann; Stephanie Hagl; Reham M Abdel-Kader; Christopher Kurz; Kristina Leuner; Walter E Muller
Journal:  Mol Neurobiol       Date:  2012-05-03       Impact factor: 5.590

6.  Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule.

Authors:  David R Abbott; Robert T Abbott; Stephen D Jenson; G Chris Fillmore; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  J Hematop       Date:  2009-02-28       Impact factor: 0.196

7.  Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family.

Authors:  Izumi Ohno; Guido Eibl; Irina Odinokova; Mouad Edderkaoui; Robert D Damoiseaux; Moussa Yazbec; Ravinder Abrol; William A Goddard; Osamu Yokosuka; Stephen J Pandol; Anna S Gukovskaya
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-09-17       Impact factor: 4.052

8.  sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell.

Authors:  Defeng Tian; Sonia G Das; Jignesh M Doshi; Jun Peng; Jialing Lin; Chengguo Xing
Journal:  Cancer Lett       Date:  2007-11-26       Impact factor: 8.679

Review 9.  Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.

Authors:  Min H Kang; C Patrick Reynolds
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

10.  The Bcl-2 antagonist HA14-1 forms a fluorescent albumin complex that can be mistaken for several oxidized ROS probes.

Authors:  David Kessel; Michael Price; John J Reiners
Journal:  Photochem Photobiol       Date:  2008-05-29       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.